Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Medicine for animals for treating and preventing avian influenza

A bird flu and veterinary drug technology, applied in pharmaceutical formulas, medical preparations containing active ingredients, peptide/protein components, etc., can solve problems affecting the quality and hygiene of meat and eggs, intestinal damage of livestock and poultry, and poor treatment effects, etc. , achieve good disease prevention and growth promotion effects, promote growth and development, prevent and treat avian influenza

Inactive Publication Date: 2007-10-31
西安亨通光华制药有限公司
View PDF0 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Although the disease can be controlled and improved by using other drugs, it can only treat the symptoms but not the root cause, and can only control the disease. The recurrence rate is high and drug residues are caused, which seriously affects the quality and hygiene of meat and egg food
Enteritis (viral, bacterial, fungal, parasitic) is a common and frequently-occurring disease in animals. There are many drugs for treating simple enteritis, and most of them have good curative effects. However, enteritis in animals often recurs or Mixed outbreaks cause severe intestinal damage in livestock and poultry, coupled with repeated use of antibiotics, the treatment effect is not good, the course of the disease is lengthy, and even the prognosis is poor, causing huge losses to the animal husbandry industry
At present, drugs for repairing intestinal damage are rare, and only some intestinal mucosal protective agents are used, but their curative effect is not obvious

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0064] Example 1: Take 1000ml of the mannan peptide solution containing mannan peptide produced by space-induced mutagenesis strains with a weight ratio of 0.5 mg / ml and pH 4.0-6.0, add 0.25 g of activated carbon, stir well, filter, and add saccharin Sodium 0.1g, add essence 0.1ml, stir well, fill and seal to make: 100ml / bottle, 250ml / bottle, 500ml / bottle, 1000ml / bottle, 2000ml / bottle, 5000ml / bottle, 10000ml / bottle, 20000ml / bottle Bottles of α-mannan peptides with different packaging specifications are sterilized by circulating steam at 121° C. for 30 minutes, inspected by light, packaged, and put on the market after passing the inspection. The specific operation is as described above.

Embodiment 2

[0065] Example 2: basically the same as Example 1, the difference is that the weight ratio of the mannan-containing peptide in the mannan-peptide solution is 3 mg / ml or 5 mg / ml.

Embodiment 3

[0066] Example 3: Take 1000ml of the mannan peptide solution produced by space-induced mutagenic strains with a content of 3mg / ml and a pH of 4.0-6.0, add 0.25g of activated carbon, stir well, filter, add 0.5g of protein sugar, and add 0.1ml of essence , Stir well, fill and seal to make α- Mannan peptide, sterilized by flowing steam at 121°C for 30 minutes, take the commercially available veterinary ribavirin raw material according to the above amount, add 50g per 1000ml, or 100g can be irradiated by gamma-rays to make 80 -100-mesh powder, undergo sterility test, light test, pack, and put it on the market after passing the test.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses an animal medicine to prevent and treat fowl flu, which is characterized by the following: incorporating 500-5000mg alpha-mannan peptide solution per 1000ml; proceeding space embarkation for optimization alpha-hemoclastic streptococcus 33# bacterial; proceeding space mutagenesis; getting strain; using as production bacterial; proceeding one grade ferment and two grade ferment; producing mannan peptide zymotic fluid; purifying the zymotic fluid; filtering; adding proper essence and correcting agent; dissolving; formulating; stirring evenly; filtering; loading; sealing; sterilizing at hot pressure; getting ferment stock solution. This invention possesses high curative effect without drug tolerance.

Description

technical field [0001] The invention relates to a veterinary medicine, in particular to a veterinary medicine capable of preventing and treating bird flu. Background technique [0002] With the development of my country's animal husbandry industry, livestock and poultry infectious diseases have become a major problem plaguing the animal husbandry industry. Livestock and poultry immune failure and low immunity often lead to complex and changeable livestock and poultry diseases, especially the morbidity and mortality of young livestock and poultry increase year by year. Old diseases have not been eliminated and new diseases continue to appear. For example, infectious bursal disease of chickens and circovirus disease of pigs can destroy the body's immune system, resulting in repeated attacks of the body. the cost of farming. There are fewer and fewer single infections, and more and more mixed infections. Livestock and poultry digestive tract diseases also continue to occur, ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K38/16A61P31/16C12P21/02
Inventor 赵恒
Owner 西安亨通光华制药有限公司
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products